Kiromic BioPharma Inc. (KRBP): What Does Valuation Ratios Tell Us?

0
1
BBAI
BBAI

Kiromic BioPharma Inc. (NASDAQ:KRBP) saw a downside of -24.08% to close Tuesday at $0.21 after subtracting -$0.07 on the day. The 5-day average trading volume is 1,367,160 shares of the company’s common stock. It has gained $0.2800 in the past week and touched a new high 2 times within the past 5 days. An average of 452,305 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 227,422.

KRBP’s 1-month performance is 19.90% or $0.0392 on its low of $0.1500 reached on 01/06/23. The company’s shares have touched a 52-week low of $0.15 and high of $1.23, with the stock’s rally to the 52-week high happening on 01/23/23. YTD, KRBP has achieved 16.38% or $0.0296 and has reached a new high 4 times. However, the current price is down -82.90% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 10.51.

Kiromic BioPharma Inc.’s quick ratio for the period ended June 29 was 0.20, with the current ratio over the same period at 0.20. The firm’s gross profit as reported stood at $12000.0 against revenue of $25.74 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 48.4% to -$11.86 million, while revenue of -$8.44 million was 28.84% off the previous quarter. Analysts expected KRBP to announce -$0.38 per share in earnings in its latest quarter, but it posted -$0.54, representing a -42.10% surprise. EBITDA for the quarter stood at more than -$7.86 million. KRBP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 12.73 million, with total debt at $2.17 million. Shareholders hold equity totaling $18.25 million.

Let’s look briefly at Kiromic BioPharma Inc. (KRBP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 49.73% to suggest the stock is trending Neutral, with historical volatility in this time period at 222.85%.

The stock’s 5-day moving average is $0.2200, reflecting a -3.35% or -$0.0073 change from its current price. KRBP is currently trading +22.70% above its 20-day SMA, -50.40% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -21.09% and SMA200 by-73.47%.

Stochastic %K and %D was 70.54% and 69.71% and the average true range (ATR) pointed at 0.0424. The RSI (14) points at 49.29%, while the 14-day stochastic is at 46.38% with the period’s ATR at 0.0387. The stock’s 9-day MACD Oscillator is pointing at 0.0139 and 0.0240 on the 14-day charts.

Analyst Ratings

LEAVE A REPLY

Please enter your comment!
Please enter your name here